Intravenous immunoglobulin and prednisolone to women with unexplained recurrent pregnancy loss after assisted reproductive technology treatment:a protocol for a randomised, double-blind, placebo-controlled trial

Autor: Caroline Nørgaard-Pedersen, Kaspar Nielsen, Rudi Steffensen, Line Eriksen, Malene Møller Jørgensen, Ulrik Schiøler Kesmodel, Ole Bjarne Christiansen

Publikováno v: Nørgaard-Pedersen, C, Nielsen, K, Steffensen, R, Eriksen, L, Jørgensen, M M, Kesmodel, U S & Christiansen, O B 2022, ' Intravenous immunoglobulin and prednisolone to women with unexplained recurrent pregnancy loss after assisted reproductive technology treatment : a protocol for a randomised, double-blind, placebo-controlled trial ', BMJ Open, vol. 12, no. 9, e064780, pp. e064780 . https://doi.org/10.1136/bmjopen-2022-064780

IntroductionRecurrent pregnancy loss (RPL), defined as two or more consecutive pregnancy losses in the first trimester, affects around 5% of fertile women. The underlying causes remain unknown in up to 60% of patients; however, most studies point at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b11c99447ea2bc8836d6c03096ca6a8
https://vbn.aau.dk/ws/files/489586770/N_rgaard_Pedersen_et_al._2022_._Intravenous_immunoglobulin_and_prednisolone_to_women_with_unexplained_recurrent_pregnancy_loss_after_assisted_reproductive_technology_treatment_a_protocol_for_a_randomised_double_blind_pla.pdf